|
Match
|
Document |
Document Title |
|
|
7615539 |
Nucleic acid-lipophilic conjugates
The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic...
|
|
|
7605138 |
Nucleic acid compositions for stimulating immune responses
The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
|
|
|
7585283 |
Device and method for examining a body lumen
A device and method is described for enabling an examining device to pass through an abnormally configured body lumen. The device may pass through a body lumen while maintaining an initial...
|
|
|
7563453 |
Compositions for controlled release of pest control products in aquatic environments
The present invention relates to compositions and methods for the controlled-release of pest control products into aquatic environments. The compositions comprise one or more pest control products...
|
|
|
7547452 |
Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may...
|
|
|
7547451 |
Pellet formulation for the treatment of the intestinal tract
An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a...
|
|
|
7541347 |
Minocycline oral dosage forms for the treatment of acne
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
|
|
|
7537785 |
Composition for treating vascular diseases characterized by nitric oxide insufficiency
The present invention provides a composition comprising an antioxidant, and at least one of isosorbide dinitrate and isosorbide mononitrate in therapeutically effective dosage of each of the...
|
|
|
7524828 |
Immunostimulatory nucleic acid molecules
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity,...
|
|
|
7524515 |
Pharmaceutical safety dosage forms
Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant...
|
|
|
7524513 |
Biofunctional fibers
The present invention is directed to surface functionalization of polymeric fibers. Surface biofunctionalization is achieved by covalent conjugation of biofunctional igands and/or cell growth...
|
|
|
7520897 |
Medical devices having antimicrobial properties
Microbial growth on the surface of a valve of a voice prosthesis and optionally the cartridge or ring supporting the valve, is inhibited by providing antimicrobial activity at a level sufficient to...
|
|
|
7514100 |
Controlled release hydrocodone formulations
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
|
|
|
7510727 |
Melt-extrusion multiparticulates
A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an...
|
|
|
7476403 |
Oral extended-release composition
The invention is directed to controlled release formulations containing drugs which are preferably considered sparingly soluble to insoluble and which are suitable for administration to a patient...
|
|
|
7470435 |
Extended release venlafaxine formulation
A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
|
|
|
7465462 |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a...
|
|
|
7445795 |
Delivery device, method of using and method of manufacturing
An active principle delivery device ( 1 ) comprising an inner capsule ( 4 ) within an outer capsule ( 2 ), the inner and outer capsules ( 4,2 ) containing the same active principle ( 5,3 ), with at...
|
|
|
7427413 |
Stable shaped particles of crystalline organic compounds
The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred...
|
|
|
7419686 |
Opioid agonist/antagonist combinations
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid...
|
|
|
7417110 |
Biodegradable polyphosphoramidates for controlled release of bioactive substances
The present invention is directed to a series of new polycationic biodegradable polyphosphoramidates. Process for making the polymers, compositions containing these polymers and bioactive ligands...
|
|
|
7408018 |
Elastomeric functional biodegradable copolyester amides and copolyester urethanes
The invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers are based on α-amino acids and possess physical, chemical...
|
|
|
7384653 |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second...
|
|
|
7374781 |
Sustained release formulations containing acetaminophen and tramadol
A sustained release formulation as a unit dose contains 100 mg-1000 mg of Acetaminophen and 15 mg-150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of...
|
|
|
7374779 |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction...
|
|
|
7314640 |
Formulation and process for drug loaded cores
The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
|
|
|
7303761 |
Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
The present invention is related to a solid pharmaceutical composition comprising two separate regions,
a first region comprising at least one non-steroidal anti-inflammatory drug (NSAID)...
|
|
|
7271156 |
Immunostimulatory nucleic acids
The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T...
|
|
|
7253249 |
Ester-terminated poly(ester-amide) in personal care products
A resin composition is prepared by reacting components comprising dibasic acid, diamine, polyol and monoalcohol, wherein (a) at least 50 equivalent percent of the dibasic acid comprises polymerized...
|
|
|
7247491 |
Method for determining release of a peptide from a sustained release polylactide formulation
A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of...
|
|
|
7214385 |
Pharmaceutical formulation containing dye
Methods and compositions for preventing abuse of dosage forms comprising an opioid analgesic and an aversive agent (e.g., a dye) in an effective amount to deter an abuser from administering a...
|
|
|
7211275 |
Composite materials for controlled release of water soluble products
Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same,...
|
|
|
7195778 |
Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
The invention is directed to a drug delivery device for controlled release of a drug, comprising a core that has a cylindrical plug embedded therein; and a coating that at least partially surrounds...
|
|
|
7195769 |
Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the...
|
|
|
7186418 |
Composition and use of RAR antagonists for promoting chondrogenesis
The invention provides compositions comprising an RAR antagonist for promoting chondrogenesis and methods employing such compositions for treating cartilage and associated bone abnormalities...
|
|
|
7182956 |
Stable topical drug delivery compositions
A stable composition of a drug comprising a carrier having a phosphatidylcholine component which entraps the drug is applied to the skin for transdermal delivery of the drug.
|
|
|
7166295 |
Methods of treatment and diagnostic visualization, particularly in cancer
Methods and reagents for improved treatment and diagnostic imaging, particularly of cancer. The methods and reagents utilize specific targeting of treatment and imaging ligands to the targeted...
|
|
|
7163694 |
Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
Bioerodible poly(ortho esters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents from dioxane-based di(ketene acetals). Block...
|
|
|
7157103 |
Pharmaceutical formulation containing irritant
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating...
|
|
|
7153840 |
Aqueous fludarabine phosphate composition
This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which...
|
|
|
7148207 |
Oral fludara of high-purity formulation with quick release of active ingredient
This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
|
|
|
7144587 |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to...
|
|
|
7141250 |
Pharmaceutical formulation containing bittering agent
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter...
|
|
|
7132108 |
Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis bacteria
Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis are administered to chickens to provide the chickens with sustained protection against S. enteritidis ...
|
|
|
7122207 |
High drug load acid labile pharmaceutical composition
A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a...
|
|
|
7118762 |
Controlled release lipoic acid
A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid...
|
|
|
7115281 |
Processes for the preparation of oral dosage formulations of modafinil
The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles...
|
|
|
7109166 |
Sustained release formulation of a peptide
This invention is directed to a sustained release composition comprised of Compound (A) having the formula
or a pharmaceutically acceptable salt thereof, and a copolymer comprised of...
|
|
|
7108866 |
Chronotherapeutic diltiazem formulations and the administration thereof
A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing...
|
|
|
7108861 |
Environmentally benign crop protection agents
Disclosed are environmentally benign crop protection compounds that interfere with the attachment of a broad range of plant pathogens to plant cells surfaces.
|